CLINICAL TRIALS PROFILE FOR CALQUENCE
✉ Email this page to a colleague
All Clinical Trials for CALQUENCE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02972840 ↗ | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Recruiting | Acerta Pharma BV | Phase 3 | 2017-04-05 | This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma. |
| NCT03516617 ↗ | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2018-09-10 | This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. |
| NCT03516617 ↗ | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | Mayo Clinic | Phase 2 | 2018-09-10 | This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. |
| NCT03580928 ↗ | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | Recruiting | Acerta Pharma | Phase 2 | 2018-07-30 | This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: - Acalabrutinib - Venetoclax - Obinutuzmab |
| NCT03580928 ↗ | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | Recruiting | Acerta Pharma, LLC | Phase 2 | 2018-07-30 | This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: - Acalabrutinib - Venetoclax - Obinutuzmab |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CALQUENCE
Condition Name
Clinical Trial Locations for CALQUENCE
Trials by Country
Clinical Trial Progress for CALQUENCE
Clinical Trial Phase
Clinical Trial Sponsors for CALQUENCE
Sponsor Name
